 Connection
Aastha Khatiwada to Humans
This is a "connection" page, showing publications Aastha Khatiwada has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.088 |
|
|
|
-
Khatiwada A, Wolf BJ, Mulligan JK, Shary JR, Hewison M, Baatz JE, Newton DA, Hawrylowicz C, Hollis BW, Wagner CL. Effects of vitamin D supplementation on circulating concentrations of growth factors and immune-mediators in healthy women during pregnancy. Pediatr Res. 2021 02; 89(3):554-562.
Score: 0.016
-
Katial JM, Hoyte FCL, Khatiwada A, Katial RK. Allergen skin test responses in broad U.S. asthma population in those with and without rhinitis. Allergy Asthma Proc. 2024 05 01; 45(3):158-165.
Score: 0.005
-
Miller JE, Oh E, Khatiwada A, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL, Beswick DM. Two-Year Impact of Highly Effective Modulator Therapy on Olfactory Dysfunction. Laryngoscope. 2024 06; 134(6):2492-2494.
Score: 0.005
-
Beswick DM, Liu CM, Overdevest JB, Zemke A, Khatiwada A, Gudis DA, Miller JE, Kimple A, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Eshaghian PH, Mace JC, Markarian K, Alt JA, Bodner TE, Chowdhury NI, Getz AE, Hwang PH, Khanwalker A, Lee JT, Li DA, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Turner GA, Wang MB, Saavedra MT, Taylor Cousar JL. Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis. Laryngoscope. 2024 09; 134(9):3965-3973.
Score: 0.005
-
Rhoads SL, Edinger J, Khatiwada A, Zimmer J, Zelarney P, Wechsler ME. The impact of insomnia and depression on asthma control. J Asthma. 2024 Oct; 61(10):1248-1251.
Score: 0.005
-
Keller L, Perera EK, Bindon B, Khatiwada A, Stitt JM, Dreskin SC. Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: A meta-analysis. Allergy Asthma Proc. 2024 03 01; 45(2):97-99.
Score: 0.005
-
Miller JE, Taylor-Cousar JL, Humphries SM, Khatiwada A, Chen H, Wilson A, Vladar EK, Lynch DA, Li DA, Beswick DM. Chronic rhinosinusitis and olfaction after highly effective modulator therapy: The role of individual sinus inflammation. Int Forum Allergy Rhinol. 2024 05; 14(5):986-989.
Score: 0.005
-
Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 06; 14(6):1079-1087.
Score: 0.005
-
Beswick DM, Khatiwada A, Miller JE, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up. J Cyst Fibros. 2024 03; 23(2):214-218.
Score: 0.005
-
Malvar A, Alberton V, Lococo B, Lourenco M, Martinez J, Burna L, Besso C, Navarro J, Nagaraja HN, Khatiwada A, Wolf B, Rovin B. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients. Lupus Sci Med. 2023 05; 10(1).
Score: 0.005
-
Gross LM, Nelson HS, Khatiwada A, Hoyte FCL. Curcumin does not significantly affect immediate skin tests. Allergy Asthma Proc. 2022 11 01; 43(6):543-545.
Score: 0.005
-
Burton HJ, Khatiwada A, Chung D, Meissner EG. Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. South Med J. 2022 06; 115(6):352-357.
Score: 0.005
-
Beswick DM, Humphries SM, Miller JE, Balkissoon CD, Khatiwada A, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol. 2022 11; 12(11):1435-1438.
Score: 0.005
-
Beswick DM, Humphries SM, Balkissoon CD, Strand M, E Miller J, Khatiwada A, Vladar EK, Lynch DA, Taylor-Cousar JL. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del. Int Forum Allergy Rhinol. 2022 07; 12(7):963-966.
Score: 0.004
-
Song NJ, Allen C, Vilgelm AE, Riesenberg BP, Weller KP, Reynolds K, Chakravarthy KB, Kumar A, Khatiwada A, Sun Z, Ma A, Chang Y, Yusuf M, Li A, Zeng C, Evans JP, Bucci D, Gunasena M, Xu M, Liyanage NPM, Bolyard C, Velegraki M, Liu SL, Ma Q, Devenport M, Liu Y, Zheng P, Malvestutto CD, Chung D, Li Z. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J Hematol Oncol. 2022 01 10; 15(1):5.
Score: 0.004
-
Ayoub I, Wolf BJ, Geng L, Song H, Khatiwada A, Tsao BP, Oates JC, Rovin BH. Prediction models of treatment response in lupus nephritis. Kidney Int. 2022 02; 101(2):379-389.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|